Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2020.03.003Source: DataRank Database

The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy is a research paper published in Clinical Genitourinary Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 25 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access25 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.41)OA: hybridTopics (86)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Rachel Beck,Valerie H. Le,James J. Hsieh ORCID,Lana Hamieh ORCID

Live enrichment

PubMed:32291161 PMC:PMC7415534 OpenAlex:https://openalex.org/W3011419056

National Institutes of Health

Grant: R01 CA223231

National Institutes of Health

Grant: 5R01CA223231-03

Genetic Loss-of-Function Studies of SETD2 in Kidney Tumorigenesis

FWCI

2.41

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2026

hybridLicense: cc-by-nc-nd

journalhttp://www.clinical-genitourinary-cancer.com/article/S1558767320300525/pdf

publisherhttp://www.clinical-genitourinary-cancer.com/article/S1558767320300525/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1558767320300525?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1558767320300525?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clgc.2020.03.003

Fields of Study

Renal cell carcinoma treatmentRenal and related cancersConnective Tissue Growth Factor Research03 medical and health sciences0302 clinical medicineAdultAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellDrug Resistance, NeoplasmEverolimusFemaleFollow-Up StudiesHumansImmunotherapyKidney NeoplasmsMaleMiddle AgedPhenylurea CompoundsPrognosisProtein Kinase InhibitorsQuinolinesSirolimusSurvival RateClear-cell metastatic renal cell carcinoma

MeSH Terms

EverolimusAdultAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellFemaleFollow-Up StudiesHumansImmunotherapyKidney NeoplasmsMaleMiddle AgedPhenylurea CompoundsPrognosisQuinolinesSurvival RateDrug Resistance, NeoplasmSirolimusProtein Kinase Inhibitors

Keywords

LenvatinibMedicineEverolimusInternal medicineOncologyTargeted therapyRenal cell carcinomaRegimenSunitinibCombination therapyCabozantinibRefractory (planetary science)Tyrosine-kinase inhibitorSorafenibCancerHepatocellular carcinomaKidney cancerMtor InhibitorPrimary RefractoryImmune Checkpoint InhibitorSecond-line Therapy Tyrosine Kinase inhibitorAdultMaleDrug Resistance616Antineoplastic Combined Chemotherapy ProtocolsMedicine and Health SciencesHumansCarcinoma, Renal CellProtein Kinase InhibitorsSirolimusPhenylurea CompoundsCarcinomaRenal CellMiddle AgedPrognosisKidney NeoplasmsSurvival RateDrug Resistance, NeoplasmQuinolinesNeoplasmFemaleImmunotherapyFollow-Up Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy

FAIR Checklist

Authors (4)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)